Long term mortality in patients with hypertrophic cardiomyopathy - A Danish nationwide study.

Background population Hypertrophic cardiomyopathy Long-term mortality Registry Sudden cardiac death

Journal

American heart journal plus : cardiology research and practice
ISSN: 2666-6022
Titre abrégé: Am Heart J Plus
Pays: United States
ID NLM: 101779333

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 27 09 2022
revised: 18 12 2022
accepted: 18 12 2022
medline: 22 12 2022
pubmed: 22 12 2022
entrez: 21 3 2024
Statut: epublish

Résumé

Patients with hypertrophic cardiomyopathy (HCM) are generally regarded as having increased risk of arrhythmia, stroke, heart failure, and sudden cardiac death, but reported mortality rates vary considerably and originate from selected populations. We aimed to investigate the long-term mortality rate in a nationwide cohort of patients with HCM compared to a matched cohort from the general Danish population. All patients with a first-time HCM diagnosis in Denmark between January 1, 2007 and December 31, 2018 were identified through nationwide registries. In the main analysis, two visits in an outpatient clinic were required in order to increase specificity. Patients were matched to controls from the background population in a 1:3 ratio based on age, sex, selected comorbidities and date of HCM. Mortalities were compared using Kaplan Meier estimator and multivariable Cox regression models. We identified 3126 patients with a first-time diagnosis of HCM. 1197 patients had at least two visits in the outpatient clinic (43 % female, median age 63.1 [25th-75th percentile 52.1-72.1] years). All-cause mortality was significantly higher in HCM patients than in matched controls: 10-year probabilities of death were 36.4 % (95 % CI 30.2-43.5 %) for HCM patients and 19.4 % (95 % CI 16.8-22.5 %) for controls. After adjusting for additional comorbidities and medications, a diagnosis with HCM was associated with an increased mortality rate (HR 1.48 (95 % CI 1.18-1.84, Compared to matched controls from the background population, presence of HCM was associated with a significant increase in mortality rate.

Sections du résumé

Background UNASSIGNED
Patients with hypertrophic cardiomyopathy (HCM) are generally regarded as having increased risk of arrhythmia, stroke, heart failure, and sudden cardiac death, but reported mortality rates vary considerably and originate from selected populations.
Study objective UNASSIGNED
We aimed to investigate the long-term mortality rate in a nationwide cohort of patients with HCM compared to a matched cohort from the general Danish population.
Methods UNASSIGNED
All patients with a first-time HCM diagnosis in Denmark between January 1, 2007 and December 31, 2018 were identified through nationwide registries. In the main analysis, two visits in an outpatient clinic were required in order to increase specificity. Patients were matched to controls from the background population in a 1:3 ratio based on age, sex, selected comorbidities and date of HCM. Mortalities were compared using Kaplan Meier estimator and multivariable Cox regression models.
Results UNASSIGNED
We identified 3126 patients with a first-time diagnosis of HCM. 1197 patients had at least two visits in the outpatient clinic (43 % female, median age 63.1 [25th-75th percentile 52.1-72.1] years). All-cause mortality was significantly higher in HCM patients than in matched controls: 10-year probabilities of death were 36.4 % (95 % CI 30.2-43.5 %) for HCM patients and 19.4 % (95 % CI 16.8-22.5 %) for controls. After adjusting for additional comorbidities and medications, a diagnosis with HCM was associated with an increased mortality rate (HR 1.48 (95 % CI 1.18-1.84,
Conclusion UNASSIGNED
Compared to matched controls from the background population, presence of HCM was associated with a significant increase in mortality rate.

Identifiants

pubmed: 38510499
doi: 10.1016/j.ahjo.2022.100244
pii: S2666-6022(22)00161-6
pmc: PMC10946047
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100244

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mads-Holger Bang Jacobsen (MB)

Dep. of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Jeppe Kofoed Petersen (JK)

Dep. of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Daniel Modin (D)

Dep. of Cardiology, Copenhagen University Hospital, Herlev and Gentofte, Kildegårdsvej 28, 2900 Hellerup, Denmark.

Jawad Haider Butt (JH)

Dep. of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Jens Jakob Thune (JJ)

Dep. of Cardiology, Copenhagen University Hospital, Bispebjerg-Frederiksberg, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark.

Henning Bundgaard (H)

Dep. of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Christian Torp Pedersen (CT)

Dep. of Clinical Research and Cardiology, Nordsjællands Hospital, Hillerød, Denmark.

Lars Køber (L)

Dep. of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Emil Loldrup Fosbøl (EL)

Dep. of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Anna Axelsson Raja (AA)

Dep. of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Classifications MeSH